# Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

> **NCT01497496** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 29 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** High Dose Methylprednisolone (HDMP)
- **DRUG:** Ofatumumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01497496
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-26
- **Primary completion:** 2019-09-25
- **Final completion:** 2020-03-20
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2021-04-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497496, "Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01497496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*